BR112017012136A2 - Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr - Google Patents
Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfrInfo
- Publication number
- BR112017012136A2 BR112017012136A2 BR112017012136-0A BR112017012136A BR112017012136A2 BR 112017012136 A2 BR112017012136 A2 BR 112017012136A2 BR 112017012136 A BR112017012136 A BR 112017012136A BR 112017012136 A2 BR112017012136 A2 BR 112017012136A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxo
- combination
- hydro
- anticancer activity
- egfr inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção refere-se a uma composição farma-cêutica de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetóxi)-pirimidin-2-il]-benzil}-6-oxo-1,6-di-hidro-piridazin-3-il)-benzonitrila ou um sal farmaceutica-mente aceitável e/ou solvato da mesma em combinação com n-[3-[[2-[4-(4-acetilpiperazin-1-il)-2-metóxi-anilino]-5-(trifluorometil)pirimidin-4-il]amino]fenil]prop-2-enamida.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14004200.3 | 2014-12-12 | ||
EP14004200 | 2014-12-12 | ||
PCT/EP2015/002265 WO2016091346A1 (en) | 2014-12-12 | 2015-11-12 | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017012136A2 true BR112017012136A2 (pt) | 2018-01-02 |
Family
ID=52133768
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017012136-0A BR112017012136A2 (pt) | 2014-12-12 | 2015-11-12 | Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr |
Country Status (17)
Country | Link |
---|---|
US (2) | US10532052B2 (pt) |
EP (1) | EP3229806A1 (pt) |
JP (1) | JP2017537939A (pt) |
KR (1) | KR20170090499A (pt) |
CN (1) | CN106999493A (pt) |
AU (1) | AU2015360005A1 (pt) |
BR (1) | BR112017012136A2 (pt) |
CA (1) | CA2970391A1 (pt) |
CL (1) | CL2017001478A1 (pt) |
IL (1) | IL252752A0 (pt) |
MX (1) | MX2017007372A (pt) |
PH (1) | PH12017500718A1 (pt) |
RU (1) | RU2017124612A (pt) |
SG (1) | SG11201704767YA (pt) |
UA (1) | UA120108C2 (pt) |
WO (1) | WO2016091346A1 (pt) |
ZA (1) | ZA201704654B (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI739206B (zh) | 2014-12-12 | 2021-09-11 | 日商日本煙草產業股份有限公司 | 二氫嘧啶-2-酮化合物及其醫藥用途 |
KR20200126973A (ko) | 2018-02-28 | 2020-11-09 | 니뽄 다바코 산교 가부시키가이샤 | 4-메틸디히드로피리미디논 화합물 및 그의 의약 용도 |
US11455294B2 (en) * | 2019-10-18 | 2022-09-27 | Sap Se | Information lifecycle management notification framework |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060188498A1 (en) | 2005-02-18 | 2006-08-24 | Genentech, Inc. | Methods of using death receptor agonists and EGFR inhibitors |
US20090155247A1 (en) | 2005-02-18 | 2009-06-18 | Ashkenazi Avi J | Methods of Using Death Receptor Agonists and EGFR Inhibitors |
DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
AU2009300328A1 (en) * | 2008-10-01 | 2010-04-08 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
CA2749012C (en) | 2009-01-08 | 2017-01-31 | Merck Patent Gmbh | Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof |
MY181898A (en) | 2010-11-01 | 2021-01-12 | Celgene Car Llc | Heterocyclic compounds and uses thereof |
MY169233A (en) | 2012-03-15 | 2019-03-19 | Celgene Car Llc | Solid forms of an epidermal growth factor receptor kinase inhibitor |
MX2014010982A (es) | 2012-03-19 | 2014-10-13 | Merck Patent Gmbh | Combinacion de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anticancerosa con otros compuestos antitumorales. |
RU2660354C2 (ru) * | 2012-04-03 | 2018-07-05 | Новартис Аг | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение |
CN104703655A (zh) | 2012-10-11 | 2015-06-10 | 默克专利股份公司 | 具有抗-癌活性的6-氧代-1,6-二氢-哒嗪衍生物与mek抑制剂的组合 |
JOP20200097A1 (ar) * | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
-
2015
- 2015-11-12 BR BR112017012136-0A patent/BR112017012136A2/pt not_active Application Discontinuation
- 2015-11-12 KR KR1020177018885A patent/KR20170090499A/ko unknown
- 2015-11-12 EP EP15794469.5A patent/EP3229806A1/en not_active Withdrawn
- 2015-11-12 RU RU2017124612A patent/RU2017124612A/ru not_active Application Discontinuation
- 2015-11-12 MX MX2017007372A patent/MX2017007372A/es unknown
- 2015-11-12 JP JP2017531477A patent/JP2017537939A/ja active Pending
- 2015-11-12 UA UAA201707191A patent/UA120108C2/uk unknown
- 2015-11-12 AU AU2015360005A patent/AU2015360005A1/en not_active Abandoned
- 2015-11-12 SG SG11201704767YA patent/SG11201704767YA/en unknown
- 2015-11-12 CA CA2970391A patent/CA2970391A1/en not_active Abandoned
- 2015-11-12 US US15/534,527 patent/US10532052B2/en not_active Expired - Fee Related
- 2015-11-12 CN CN201580067628.6A patent/CN106999493A/zh active Pending
- 2015-11-12 WO PCT/EP2015/002265 patent/WO2016091346A1/en active Application Filing
-
2017
- 2017-04-18 PH PH12017500718A patent/PH12017500718A1/en unknown
- 2017-06-07 IL IL252752A patent/IL252752A0/en unknown
- 2017-06-09 CL CL2017001478A patent/CL2017001478A1/es unknown
- 2017-07-11 ZA ZA2017/04654A patent/ZA201704654B/en unknown
-
2019
- 2019-09-06 US US16/563,018 patent/US20190388423A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2016091346A1 (en) | 2016-06-16 |
PH12017500718A1 (en) | 2017-10-09 |
RU2017124612A (ru) | 2019-01-14 |
US10532052B2 (en) | 2020-01-14 |
KR20170090499A (ko) | 2017-08-07 |
CL2017001478A1 (es) | 2018-01-05 |
SG11201704767YA (en) | 2017-07-28 |
JP2017537939A (ja) | 2017-12-21 |
RU2017124612A3 (pt) | 2019-06-05 |
UA120108C2 (uk) | 2019-10-10 |
US20190388423A1 (en) | 2019-12-26 |
CA2970391A1 (en) | 2016-06-16 |
ZA201704654B (en) | 2019-08-28 |
AU2015360005A1 (en) | 2017-07-27 |
IL252752A0 (en) | 2017-08-31 |
US20170319581A1 (en) | 2017-11-09 |
MX2017007372A (es) | 2017-11-06 |
CN106999493A (zh) | 2017-08-01 |
EP3229806A1 (en) | 2017-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124998T1 (el) | Ετεροκυκλικες ενωσεις και χρήσεις αυτων | |
EA201691872A1 (ru) | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств | |
MD3464265T2 (ro) | Polimorfi de N-[(3-fluoro-4-metoxipiridin-2-il)metil]-3-(metoximetil)-1-({4-[2-oxopiridin-1-il)metil]fenil}metil)pirazol-4-carboxamidă ca inhibitori de kalicreină | |
CY1121421T1 (el) | Φαρμακοτεχνικες μορφες | |
DK2373640T3 (da) | Hidtil ukendte polymorfe former af 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitril-hydrochloridsalt og fremgangsmåder til fremstilling deraf | |
EA202091120A2 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
BR112019004356A2 (pt) | composições de comprimido | |
BR112017012136A2 (pt) | Combinação de um derivado de 6-oxo-1,6-di-hidro- piridazina tendo atividade anticâncer com um inibidor de egfr | |
BR112015010121A2 (pt) | inibidores de quinase de tirosina de bruton | |
PH12017500719A1 (en) | Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative | |
ECSP099673A (es) | Formas sólidas de un inhibidor de cinasa raf | |
ES2421587T3 (es) | Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica | |
BR112015030171A2 (pt) | composto, composição farmacêutica, método para prevenir ou tratar uma doença ou seus sintomas, uma afecção ou um distúrbio mediado parcial ou completamente por receptores nicotínicos de acetilcolina, uso de 4-(5-(4- clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol-3-il) benzenossulfonamida | |
EA202091279A1 (ru) | Полиморфы и твердые формы пиримидиниламино-пиразолового соединения и способы их получения | |
PE20170926A1 (es) | Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson | |
BR112015007870A2 (pt) | combinação de um derivado de 6-oxo-1,6-di-hidro-piridazina tendo atividade anticâncer com um inibidor de mek | |
PH12016500948A1 (en) | Combination of a 6-oxo- 1,6-dihydro-pyridazine derivate having anti-cancer activity with gefitinib | |
MA35636B1 (fr) | Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide | |
BR112015008279A2 (pt) | derivado de 6-oxo-1,6-di-hidro-piridazina para uso no tratamento de carcinoma hepatocelular (hcc) | |
BR112017012547A2 (pt) | Composições de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h- indazol-5-il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il) fenil)-3,6-diidropiridin-1(2h)-il)-2-oxoetil)-3-(metiltio) pirrolidina-3-carboxamida para preparações farmacêuticas | |
BR112022000266A2 (pt) | Preparação farmacêutica | |
DK3585776T3 (da) | 5-(pyrimidin-4-yl)-2-(pyrrolidin-1-yl)nicotinonitril-forbindelser som ikke, tbk1 og/eller sik2 kinaseinhibitorer | |
EA201591300A1 (ru) | Формы меглуминовой соли 2-((1r,4r)-4-(4-(5-(бензоксазол-2-иламино)пиридин-2-ил)фенил)циклогексил)уксусной кислоты и их применение в качестве ингибиторов dgat1 | |
PH12016500964A1 (en) | A 6-oxo-1,6-dihydro-pyridazine derivative for the use for the treatment of renal cell carcinoma (rcc) | |
BR112021024194A2 (pt) | Formulação de liberação modificada de um composto de pirimidinilamino-pirazol e métodos de tratamento |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |